Zivo Bioscience, Inc. (NASDAQ:ZIVO) recently reported a significant stock acquisition by a major shareholder. Mark E. Strome, through Strome Investment Management LP and Strome Group, Inc., acquired 75,000 shares of Zivo Bioscience’s common stock on December 26, 2024, at a price of $20.19 per share, totaling approximately $1.51 million. The stock, which has delivered an impressive 1,640% return year-to-date according to InvestingPro data, currently trades near $20.89 and appears slightly undervalued based on Fair Value analysis. This transaction increases the total shares owned by the reporting entities to 398,683.
Additionally, a related transaction involved the acquisition of 7,500 common stock purchase warrants, which were exercised at no cost on the same date. These transactions reflect strategic moves by Strome’s entities, which hold a significant stake in the company.
In other recent news, Zivo Bioscience has made significant moves in its financial operations. The Nevada-based biotech company has restructured its existing debt with three creditors, issuing unsecured promissory notes totaling approximately $277,254.38. The creditors involved are Howard Shapiro, Merger Masters Pension Fund, and Financial Trading Consultants Pension Fund, who accepted the notes in exchange for settling outstanding debts.
These notes will be repaid over a 24-month period starting from November 2024, carrying a nominal interest rate of 1.0% per annum. In the event of default, the creditors hold the right to demand immediate payment of the unpaid principal.
In parallel to debt restructuring, Zivo Bioscience has sold 169,022 shares of its common stock to several accredited investors. The transactions took place between August and October, with shares sold at prices ranging from $8.34 to $16.31, averaging $10.44 per share. Notably, sales to related parties accounted for 52,802 shares, sold at prices between $8.34 and $15.96, averaging $9.68 per share.
These recent developments reflect Zivo Bioscience’s strategic financial management, providing the company with additional operational flexibility.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
